Emerging role of PARP-1 and PARthanatos in ischemic stroke

J Neurochem. 2022 Jan;160(1):74-87. doi: 10.1111/jnc.15464. Epub 2021 Jul 28.

Abstract

Cell death is a key feature of neurological diseases, including stroke and neurodegenerative disorders. Studies in a variety of ischemic/hypoxic mouse models demonstrate that poly(ADP-ribose) polymerase 1 (PARP-1)-dependent cell death, also named PARthanatos, plays a pivotal role in ischemic neuronal cell death and disease progress. PARthanatos has its unique triggers, processors, and executors that convey a highly orchestrated and programmed signaling cascade. In addition to its role in gene transcription, DNA damage repair, and energy homeostasis through PARylation of its various targets, PARP-1 activation in neuron and glia attributes to brain damage following ischemia/reperfusion. Pharmacological inhibition or genetic deletion of PARP-1 reduces infarct volume, eliminates inflammation, and improves recovery of neurological functions in stroke. Here, we reviewed the role of PARP-1 and PARthanatos in stroke and their therapeutic potential.

Keywords: NAD+; PARP-1; PARthanatos; oxidative stress; stroke.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Humans
  • Ischemic Stroke / metabolism*
  • Ischemic Stroke / pathology*
  • Parthanatos / physiology*
  • Poly (ADP-Ribose) Polymerase-1 / metabolism*

Substances

  • Poly (ADP-Ribose) Polymerase-1